Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a life sciences company developing a single-molecule proteomics platform designed to enable large-scale protein measurement for research and drug discovery. The company went public in 2021 through a business combination with Arya Sciences Acquisition Corp III, a SPAC sponsored by Arya Sciences, and has traded under the NAUT ticker since the de-SPAC merger closed on Nasdaq. In April 2026, Nautilus filed a DEF 14A definitive proxy statement with the SEC ahead of its annual shareholder meeting, reflecting its continued operation as a publicly traded biotechnology company. Sign up for full data, filings, and SPAC history on NAUT at SpacDesk.